Dynavax projects HEPLISAV-B revenue of $305M-$325M for 2025 amid expanding hepatitis B market
Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.
GEN19h
HBV’s Ability to Infect Human Liver Cells Thwarted by Potential Anticancer Drug
Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.